Vascular Perfusion Solutions

What Vascular Perfusion Solutions does

Vascular Perfusion Solutions, Inc. (VPS) is a preclinical-stage medical device company developing the VP.S ENCORE, a portable hypothermic oxygenated perfusion (HOP) system for donor heart preservation. The device maintains donor hearts at controlled low temperatures (4-10°C) using oxygenated crystalloid perfusate, eliminating the need for donor blood and featuring a fail-safe mode that automatically reverts to cold static storage if perfusion is disrupted. The company spun off from UT Health San Antonio in 2019, won the 2019 Create the Future Design Contest (Grand Prize, Medical category) for its predecessor ULiSSES platform, and secured FDA Breakthrough Device Designation for the VP.S ENCORE in February 2021. Its portfolio also includes VP.S ENCORE PEDS, a pediatric variant under development for children aged 0-5 years.

Name

Vascular Perfusion Solutions

Legal name

Vascular Perfusion Solutions, Inc.

Website

https://vascularperfusion.solutions

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Vascular Perfusion Solutions is a preclinical-stage medical device company developing the portable VP.S ENCORE hypothermic oxygenated perfusion system to extend donor heart viability, targeting Organ Procurement Organizations and heart transplant centers.

Ownership category

akta.pro rank

Product category

Organ Preservation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Organ preservation devices
• Cardiac perfusion systems
• Hypothermic oxygenated perfusion
• Transplant medical devices
• Donor heart preservation

Headquarters

HQ city

San Antonio

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: VP.S ENCORE is an investigational device currently in preclinical development under FDA Breakthrough Device Designation and not yet approved for commercial use. Revenue model will be based on device sales to OPOs and transplant centers, likely with associated consumables and support services.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Vascular Perfusion Solutions develops the VP.S ENCORE, a portable hypothermic oxygenated perfusion system for cardiac preservation. The investigational medical device extends donor heart viability up to 8 hours (clinical target) using oxygenated crystalloid perfusate without blood products, with a fail-safe mode defaulting to cold static storage if perfusion fails. The portfolio also includes the pediatric VP.S ENCORE PEDS variant for children aged 0-5 and the earlier ULiSSES organ and limb preservation system.

Product overview

Vascular Perfusion Solutions offers a unified product portfolio centered on the VP.S ENCORE platform - a portable hypothermic oxygenated perfusion system for cardiac preservation. The core VP.S ENCORE device extends donor heart viability without requiring blood products, featuring built-in fail-safe cold storage capability. The portfolio includes the pediatric-specific VP.S ENCORE PEDS variant for young children and the earlier-generation ULiSSES system (organ and limb preservation) which demonstrated 24-hour preservation capability.

Differentiator

Problem solved

Functional benefit

Brands

• VP.S ENCORE®: A portable, hypothermic oxygenated perfusion system for cardiac preservation, designed to extend donor heart viability up to 8 hours with FDA Breakthrough Device Designation.
• VP.S ENCORE® PEDS™

Products and services

• VP.S ENCORE A portable hypothermic oxygenated perfusion (HOP) cardiac preservation system for OPOs and transplant centers that extends donor heart viability up to 8 hours (clinical target; preclinical data suggest up to 24 hours). Uses FDA-approved crystalloid perfusate (no donor blood required), passive cooling at 4-10°C, and a built-in fail-safe mode that defaults to cold static storage if perfusion is disrupted. Currently an investigational device under FDA Breakthrough Device Designation, not yet approved for commercial use.
• VP.S ENCORE PEDS A specialized portable pediatric heart transplant preservation device based on the VP.S ENCORE platform, designed for children aged 0-5 years with modifications for smaller organ sizes.
• ULiSSES A self-contained system for organ and limb preservation; the company's earlier-generation device that demonstrated 24-hour preservation of human hearts outside the body. Now a legacy product superseded by the VP.S ENCORE platform.

Quantifiable outcome

• Preclinical studies show stable cardiac weight with no/minimal edema after 24-hour preservation
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Wyss Institute at Harvard UniversitycoreStrategic or Co-development Partner · 1 November 2025Collaboration with Wyss Institute, University of Colorado, and University of Wyoming to develop advanced biostasis compounds for organ preservation, supported by the ARPA-H Tissue Preservation under Stress project. Focuses on translational testing of biostasis compounds to extend organ preservation time and increase donor organ utilization. VPS CEO Rafael Veraza is co-author on eLife publication with Wyss Institute researchers on pharmacological inducers of reversible hypometabolic state.
• University of ColoradocoreStrategic or Co-development Partner · 1 November 2025Collaboration with Wyss Institute, University of Colorado, and University of Wyoming to develop advanced biostasis compounds for organ preservation under ARPA-H Tissue Preservation under Stress project.
• University of WyomingcoreStrategic or Co-development Partner · 1 November 2025Collaboration with Wyss Institute, University of Colorado, and University of Wyoming to develop advanced biostasis compounds for organ preservation under ARPA-H Tissue Preservation under Stress project.
• Unravel BiosciencescoreStrategic or Co-development Partner · 1 November 2023Partnership to modulate endothelial activation during heart preservation to improve heart transplant outcomes, announced November 2023.
• Wyss Institute and U.S. Air ForcecoreStrategic or Co-development Partner · 1 April 2022Collaboration with Wyss Institute and U.S. Air Force to study compounds to improve organ transplant, announced April 2022.
• Texas Organ Sharing AlliancecoreStrategic or Co-development Partner · 1 February 2022Partnership with Texas Organ Sharing Alliance (TOSA), South Central Texas' Organ Procurement Organization, to advance heart transplant technology. Non-utilized human hearts were obtained from TOSA for VP.S ENCORE research studies.
• Biocom CaliforniaminorStrategic or Co-development PartnerVPS is a proud member of Biocom California, a life science industry association providing networking and advocacy support.
• Duke UniversityminorStrategic or Co-development PartnerListed as a collaboration partner, indicating ongoing research or development relationship with Duke University.
• Ochre BiominorStrategic or Co-development PartnerListed as a collaboration partner in organ preservation technology development.
• The Texas Heart InstitutecoreStrategic or Co-development PartnerVPS conducts porcine transplant studies at The Texas Heart Institute. Multiple scientific advisory board members from Texas Heart Institute including Dr. Bud Frazier, Dr. Marco Morales Garza, and Dr. William Cohn. Scientists from Texas Heart Institute have presented findings at Gordon Research Conferences.
• Baylor St. Luke's Medical CentercoreStrategic or Co-development PartnerDr. Alexis E. Shafii serves as Cardiothoracic Surgeon and Surgical director of the heart transplant program at Baylor St. Luke's Medical Center, serving on VPS Scientific & Clinical Advisory Board.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• TransMedics: TransMedics is the closest direct competitor, commercializing the Organ Care System for heart, lung, and liver preservation. Both companies target OPOs and transplant centers with portable ex-vivo organ perfusion technology and overlap directly in cardiac preservation.
• XVIVO Perfusion: XVIVO Perfusion (listed in Sweden) develops machine perfusion and preservation solutions for lungs, hearts, and other organs. It directly overlaps with VPS in cardiac and multi-organ hypothermic/oxygenated perfusion targeting transplant centers.

Emerging players

• OrganOx: OrganOx commercializes the metra device for normothermic liver perfusion. While focused on liver rather than heart, it competes in the same ex-vivo organ perfusion category with similar OPO/transplant center customers and engineering challenges.
• Paragonix Technologies: Paragonix develops portable hypothermic organ preservation and transport devices (e.g., SherpaPak for hearts). It is a direct competitor in portable cardiac preservation, addressing similar OPO and transplant center pain points with a non-perfusion cold storage approach.
• Bridge to Life: Bridge to Life (formerly Organ Recovery Systems) provides static cold storage and perfusion solutions, including LifePort kidney and LKT 200 for liver transport. It is an established preservation vendor to OPOs and transplant centers, overlapping with VPS's customer base.
• Tevosol: Tevosol is developing ex-vivo machine perfusion devices for lung and other organ preservation. It is a smaller emerging competitor in the broader organ perfusion space, with potential overlap in clinical and engineering approaches to VPS.
• Lung Bioengineering: Lung Bioengineering (a United Therapeutics subsidiary) operates ex-vivo lung perfusion services (XVIVO-based) for OPOs. It is adjacent in organ perfusion business models and shares OPO customer relationships with VPS.
• Preservation Solutions: Preservation Solutions provides perfusate solutions and static cold storage products used by OPOs and transplant centers. It supplies critical consumables adjacent to VPS's intended perfusate-based workflow.

Broad incumbents

• Institut Georges Lopez (IGL): IGL is a long-established supplier of organ preservation solutions (e.g., Custodiol HTK, SCOT 30) used globally for static cold storage. It is a broad incumbent in the preservation workflow that VPS targets for disruption.

Others

• TissueGen: TissueGen is an enabling technology company in bioresorbable materials and drug delivery, adjacent to biostasis and organ preservation research. It is thematically related to the biostasis compound development VPS is pursuing with Wyss Institute and ARPA-H.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vascular-perfusion-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vascular Perfusion Solutions